THE ROLE OF THE TETRASPANINS CD37 AND CD82 IN LEUKOCYTE MIGRATION
Funder
National Health and Medical Research Council
Funding Amount
$370,902.00
Summary
White blood cells must be able to migrate to fight infection. For instance, immune responses are started by the migration of one type of white blood cells to the lymph node. Also, once activated white blood cells migrate out of the circulation to the site of infection where they can kill bacteria and viruses. This grant studies 2 proteins that control white blood cell migration. These proteins may one day be targets for drugs that either promote immunity or reduce inflammation.
A Novel Molecular Mechanism Controlling Myelopoiesis
Funder
National Health and Medical Research Council
Funding Amount
$878,439.00
Summary
The immune system is comprised of many different cell types, each with a specialised function. Many are short-lived and must be continually replenished throughout life. Abnormalities in this process underlie many human diseases, including immunodeficiency, autoimmunity and cancer. We have discovered a novel molecular mechanism that is critical for the production of immune cells. This project will investigate how this mechanism is controlled and the impacts on myelodysplastic syndromes.
Making Sense Of Novel Ocular Neuroimmune Interactions.
Funder
National Health and Medical Research Council
Funding Amount
$436,178.00
Summary
It is becoming clear that the interaction between corneal nerves and immune cells underpin many inflammatory conditions of the ocular surface. Despite this increased interest, very little is known about the relationship between corneal nerves and immune cells in this outermost layer of the eye. This project will investigate the relationship between corneal nerves and immune cells during health and corneal inflammation to identify therapeutic targets to treat corneal disease.
Mechanisms Of Alpha-hemolysin Induced Immunoevasion By Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$465,475.00
Summary
S. aureus infections represent a serious global health problem. Currently, no vaccination is available demanding a better understanding of the immune response against this bacterium. We will test the hypothesis that S. aureus alpha-hemolysin represses the migration of innate immune cells to sites of cutaneous infection resulting in diminished immunity. Unraveling the mechanism behind this phenomenon will pave the way to better prophylactic and therapeutic measures against S. aureus infections.
Defining The Role Of The Major Subsets Of Renal Mononuclear Phogocytes
Funder
National Health and Medical Research Council
Funding Amount
$614,227.00
Summary
Chronic Kidney Disease (CKD) is a major cause of death and morbidity in Australia, and currently therapeutic options are limited. Renal mononuclear phagocytes (rMP) are important immune cells which play a central role in health and disease of the kidney. However, rMP are a heterogenous group of cells with a poorly defined role in the development and progression of CKD. We will define the role of major subsets of rMP in CKD, and explore their potential for treating CKD.
Targeting Antigen To Clec9A On Dendritic Cell For Humoral Immunity
Funder
National Health and Medical Research Council
Funding Amount
$744,624.00
Summary
Dendritic cells capture infectious organisms and display them to other immune cells to initiate immunity. The process of capturing organisms requires dendritic cells to express a variety of cell-surface receptors that detect components carried by infectious agents. Here we will examine the efficacy of attaching vaccine components to a targeting agent that binds one of these receptors with the aim of enabling dendritic cells to efficiently kick-start immunity against vaccine components.
Therapeutic Potential Of Peritoneal Mononuclear Phagocytes From Peritoneal Dialysis Patients
Funder
National Health and Medical Research Council
Funding Amount
$375,817.00
Summary
Mononuclear phagocytes (MP) are key cells which are now being used to treat various diseases. In Australia, more than 10 million end stage kidney disease(ESKD) patients are treated with chronic dialysis, and more than 20% of them are on peritoneal dialysis (PD). Each PD patient discards more than 20 million MP in dialysate daily. We will explore the possibility of using these MP to treat diseases including transplant rejection.
Defining The Role Of Kidney CD103+Dendritic Cells For Treatment Of Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$599,431.00
Summary
Chronic kidney disease (CKD) is a major cause of death and morbidity. Current treatments for CKD are not effective and new therapeutic approaches are needed. Dendritic cells (DCs) are key immune cells and play a central role in kidney disease. We recently found that a major DC subset called CD103+ DCs harmed the kidney in an animal model of human CKD. This study is to determine how CD103+ DCs cause kidney damage, and how to target CD103+ DCs for development of new therapies for human CKD.
Pathogenic Dendritic Cells In Human Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$370,983.00
Summary
The cost of treating end stage kidney disease in Australia is more than a billion dollars per year. Kidney disease is associated with an influx of inflammatory cells. However, current therapeutics fail to target this process due to our poor understanding of inflammatory immune cells in disease progression. This project will investigate the biology of immune cells in human kidney disease. I believe that this study will inform more accurate diagnoses and improved treatments for patients.
Exploring The Contribution Of Interferon-lambda To Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$833,235.00
Summary
We have found that a novel protein, normally made in response to viral infections, is found in the blood of Lupus patients. This project will determine the cells that make this protein, what in Lupus blood makes these cells produce it and whether it plays a role in the severity of Lupus disease.